Global Burden of Cardiovascular Disease
Cardiovascular diseases (CVDs), including heart attack and stroke, are the leading cause of death globally. According to WHO, 17.3 million people died from CVDs in 2008. Of those, an estimated 7.3 million deaths were due to coronary heart disease and 6.2 million were due to stroke.
Behavioral risk factors such as smoking, unhealthy diet, and alcohol abuse are believed to be responsible for 80% of coronary heart disease and cerebrovascular disease. Moreover, these behaviors result in increased body weight, elevated blood pressure, dyslipidemia, insulin resistance, and hyperglycemia. These effects are associated with the development of atherosclerosis, which is the main underlying cause of heart attack, stroke, and peripheral vascular disease.
Oxidative stress and inflammation are widely recognized as contributing factors to atherosclerotic CVDs. The use of antioxidants such vitamin E, C, and beta-carotene as preventive therapies for CVDs has yielded mixed results. This is why astaxanthin, which is a much stronger antioxidant that also exhibits anti-inflammatory properties, is now being investigated as a promising compound for protecting against atherosclerotic CVDs. Studies have shown that natural astaxanthin reduces oxidative stress and inflammation, improves lipid profiles, promotes better blood flow in capillaries, and lowers blood pressure in hypertensive individuals. Importantly, no adverse effects have been reported in these studies.
A large body of clinical and experimental research strongly suggests that astaxanthin can contribute to improved cardiovascular health. For more details on how natural astaxanthin can help support and maintain good cardiovascular health, please contact us for an expanded version of this digest.
Selected AstaReal Astaxanthin Research
Augusti PR et al., Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits. J Clin Biochem Nutr. 2012;51(1):42-49.
Choi HD et al., Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother Res: PTR. 2011;25(12):1813-18.
Yoshida H et al., Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis. 2010;209(2):520-23.
Iwabayashi M et al., Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden. Anti-aging medicine. 2009;6(4):15-21.
Miyawaki H et al., Effects of astaxanthin on human blood. J Clin Biochem Nutr. 2008;43(2):69-74.
Hussein G et al., Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life sciences. Life Sci. 2007;80(6):522-29.
Hussein G et al., Antihypertensive potential and mechanism of action of astaxanthin:II. vascular reactivity and hemorheology in spontaneously hypertensive. Biol Pharm Bull. 2005;28(6):967-71.
Kim KY et al., The effects of astaxanthin supplements on lipid peroxidation and antioxidant status in postmenopausal women. Nutritional Sciences. 2004;7(1):41-46.
- How does astaxanthin combat Aging?
- Unique Cell Membrane Protection
- Effective mitochondrial protection
- Enhancement of blood antioxidant capacity
- No Pro-oxidant activity
- Potent anti-inflammatory action
- Reduction of DNA Damage